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Abstract
Background: Conducting a health technology assessment (HTA) of public health interventions (PHIs) poses some
challenges. PHIs are often complex interventions, which affect the number and degree of interactions of the
aspects to be assessed. Randomized controlled trials on PHIs are rare as they are difficult to conduct because of
ethical or feasibility issues.
The aim of this study is to provide an overview of the methodological characteristics and to compare the applied
assessment methods in HTAs on PHIs.
Methods: We will systematically search HTA agencies for HTAs on PHIs published between 2012 and 2016. We will
identify the HTAs by screening the webpages of members of international HTA organizations. One reviewer will
screen the list of HTAs on the webpages of members of international HTA organization, and a second review will
double-check the excluded records. For this methodological review, we define a PHI as a population-based
intervention on health promotion or for primary prevention of chronic or non-chronic diseases. Only full HTA
reports will be included. At maximum, we will include a sample of 100 HTAs. In the case that we identify more
than 100 relevant HTAs, we will perform a random selection. We will extract data on effectiveness, safety and
economic as well as on social, cultural, ethical and legal aspects in a priori piloted standardized tables. We will not
assess the risk of bias as we focus on exploring methodological features. Data extraction will be performed by one
reviewer and verified by a second. We will synthesize data using tables and in a structured narrative way.
Discussion: Our analysis will provide a comprehensive and current overview of methods applied in HTAs on PHIs.
We will discuss approaches that may be promising to overcome the challenges of evaluating PHIs.
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Background
Health technology assessment (HTA) has become an im-
portant tool to support health policy decisions in many
countries [1]. The majority of HTAs still focus on clin-
ical medicine, in particular on pharmaceuticals. HTAs of
public health interventions (PHIs) are still rare [2]. A
2010 survey conducted in five countries found that three
in four HTAs covered a clinical topic, but only 5% of
HTAs were on a public health issue [3].
HTA of PHIs poses some challenges [4]. PHIs tend
to be highly complex due to varying intervention
components (e.g. educational, psychological, or socio-
logical), participants, contextual factors and multiple
causal pathways [5]. Randomized controlled trials
(RCTs) are often the most important data source for
effectiveness in HTAs. However, RCTs on PHIs are
often difficult to conduct because of ethical or feasi-
bility issues. This leads to a lack of RCTs on PHIs
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[6]. HTAs on PHIs often have to rely on other study
designs, in particular quasi-experimental designs such
as controlled before-after studies or interrupted time
series that are more prone to cofounding than RCTs.
Because of these challenges, the standard tools for
HTA (e.g. electronic databases, risk of bias assess-
ment) are often not fit for purpose and may not even
be applicable at all for PHIs [7, 8].
HTA agencies prepare HTAs on PHIs and conse-
quently have to deal with these challenges. Only few
HTA agencies have standardized, formalized methods
specific for HTAs on PHIs, and the few suggested ap-
proaches are heterogeneous [8].
There is no systematic analysis on the methods applied
in HTAs on PHIs. The aim of this study is to provide an
overview of the methodological characteristics and to
compare the assessment methods that have been applied
in HTAs of PHIs. More specifically, our purpose is to
get deeper insights into the approaches that are actually
applied to deal with the challenges arising in HTAs of
PHIs.
Methods/design
We used the PRISMA-P checklist [9] for guiding the
preparation of this protocol. Not all items of the check-
list were applicable due to the nature of this work (see
Additional file 1).
As no outcome of direct patient or clinical relevance is
assessed in this work, the protocol could not be regis-
tered in PROSPERO.
Searches
We will systematically search the webpages of the inter-
national umbrella organizations for systematic reviews
and national HTA agencies. We will identify the HTA
agencies by using the member lists of the following HTA
umbrella organizations: the International Network of
Agencies for Health Technology Assessment (INAHTA),
Health Technology Assessment International (HTAi) and
the European Network for Health Technology Assessment
(EUnetHTA; 06/2016: 115 organizations). Because PHIs
are very diverse, numerous search terms can be potentially
relevant. Therefore, we will not use search terms for
searching the webpages but screen the full lists of all
published HTAs. One reviewer will perform the searches.
References will be managed with EndNote X7.
Inclusion criteria
Two reviewers will independently screen potentially
relevant reports according to the following inclusion
criteria:
1. Full HTA report as defined by INAHTA (see details
below) [10]
2. Assessment of a public health intervention
3. Publication date: 2012 to 2016
4. Language: English, German, Spanish and French
We will apply the following key aspects of the
INAHTA definition of full HTA reports for study selec-
tion [10]:
○ Always
• Evaluate safety and effectiveness issues.
• Determine the cost-effectiveness of the technology,
e.g. through economic modelling (when it is
appropriate).
○ Always conduct a comprehensive systematic
literature review or a systematic review of high-level
evidence.
○ Always critically appraise the quality of the evidence
base.
○ Optionally address ethical, social and legal
considerations.
We will exclude all literature review-based HTAs
using accelerated (e.g. rapid reviews) or abbreviated
HTA/systematic review methods, overviews of reviews
(or umbrella reviews), scoping reviews, mini-HTAs,
etc. [10, 11]. We will exclude protocols for HTAs be-
cause we are primarily interested in the actual appli-
cation of methods for dealing with the challenges
when evaluating a PHI.
Public health is a broad discipline and not homoge-
neously defined in the literature. In this review, we will
consider only population-based interventions on health
promotion and interventions for primary prevention of
chronic (e.g. cardiovascular diseases, diabetes and
non-communicable [e.g. injury]) or infectious disease to
ensure consistent study selection [12]. We will exclude
HTAs on screening and vaccination because these re-
quire special evaluation methods (e.g. diagnostic accur-
acy studies, modelling) [13].
As our intention is to provide an overview of the cur-
rently applied approaches, we will include only reports
published in the last 5 years (2012–2016). In case that a
HTA agency published more than ten relevant HTAs
within the past 5 years, we will randomly select ten re-
ports of this agency to avoid overrepresentation of one
HTA agency. We will include a maximum of 100 HTAs
in the analysis. In the case that this threshold is
exceeded, we will adapt the maximum number of HTAs
per agency accordingly. We will include at least one re-
port for each agency, even when the threshold of 100
HTAs will be exceeded.
One reviewer will screen all abstracts and full texts,
and a second reviewer will screen the excluded records
only (liberal acceleration).
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A flow diagram will illustrate the selection process,
and we will provide a list of the excluded HTA reports
to ensure transparency of the selection process.
Data extraction
We will prepare standardized tables for data extraction.
We will pilot the data extraction tables before the con-
duction of the review with HTAs published before 2012.
Two reviewers will independently extract the data.
For all HTA reports, we will extract data on (i) population
and (ii) intervention characteristics, (iii) country of origin,
(iv) review planning, (v) definition of the research question
and (vi) the development of the theoretical framework/the-
ory of change.
Furthermore, we will extract detailed information on
the applied methods for each domain (effectiveness,
safety and economic as well as on social, cultural, ethical
and legal aspects).
Health (effectiveness/safety) aspects
If the assessment is based on a systematic review, then
we will extract data on the following issues:
 Included study designs (e.g. interrupted time series)
 Search strategy (electronic databases and additional
searches)
 Data extraction (items, method, involved reviewers)
 Risk of bias/quality assessment (tool, method,
involved reviewers)
 Considering context/setting in the assessment
 Assessment of applicability/generalizability (tool,
method, involved reviewers)
 Assessment of intervention integrity
 Assessment of sustainability
 Assessment of heterogeneity
 Integration qualitative and quantitative studies
 Information on subgroups (see below)
Many different primary study types (e.g. surveys) or
synthesis methods (e.g. rapid reviews) can be used in
addition to full systematic reviews to assess the effective-
ness of (complex) health interventions [14–16]. We will
also extract data on features of other synthesis methods
than “traditional” systematic reviews (e.g. realist reviews)
and on other assessment methods such as trials, surveys
and expert reviews.
Economic aspects
Also, the economic evaluation of PHIs presents some
additional methodological challenges. Methodological
challenges refer to the complexity of the intervention,
the choice of comparators and the consideration of mul-
tiple or intermediate outcomes. These issues often re-
quire complex modelling techniques.
In the economic domain, we will consider whether
a primary economic evaluation and/or a systematic
literature search of existing economic evaluations is
performed.
For primary economic evaluations, we will extract the
following information:
 Type of economic evaluation
 Choice of comparators
 Time/analysis horizon
 Perspective of analysis
 Costs considered (e.g. direct medical costs, indirect
costs)
 Sources/measurement of costs
 Valuating resources (pricing)
 Sources/measurement of outcomes
 Valuation of outcomes (e.g. time-trade-off )
 Discounting
 Modelling approach (e.g. Markov model, system
dynamics)
 Sensitivity analysis
 Presentation of results
For systematic reviews of economic evaluations, we
will extract:
 Scope of the systematic review (exclusively a
systematic review of economic evaluations or
systematic review to inform primary economic
evaluation)
 Included economic evaluation types
 Literature search strategy (databases, additional
sources, involved reviewers)
 Data extraction (items, method)
 Assessment of methodological quality (tool, method)
 Assessment of generalizability/transferability/
applicability (tools, procedure)
 Presentation of cost data (e.g. currency conversion)
 Method for data synthesis (narrative, graphical,
meta-analysis)
Furthermore, we will consider if the results of the eco-
nomic evaluation can explicitly influence the final deci-
sion (e.g. through a cost-effectiveness threshold).
We will extract whether the HTA includes a budged
impact analysis but no details on the methods for the
budget impact analysis.
Social and cultural aspects
If social and cultural aspects are considered, then we will
extract information on [17]:
 The social and cultural aspects addressed
 Theoretical framework chosen
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 Assessment method chosen
– Quantitative
– Qualitative
– Mixed methods
– Literature review of qualitative and/or
quantitative studies
 Explicit implications for the HTA
Legal aspects
Information on the approaches for considering legal as-
pects will be extracted. We will consider the following
legal aspects [15]:
 Informed consent
 Alternative forms of consent
 Privacy and data protection
 Market authorization of medical devices and
medicinal products
 Clinical trials
 Intellectual properties
 Reimbursement in public health care systems
 Special medical fields
There is no standardized approach for incorporating
legal aspects [18]. Therefore, we will further specify the
data extraction for legal aspects after the literature
screening.
Ethical aspects
If possible, we will extract information on:
 The ethical issues addressed
 The normative framework chosen
 The methods employed for arriving at
recommendations
 Explicit implications for the HTA
As this part of systematic reviews is largely under-
developed and no clear standards are formulated, we are
not able to predict what approaches were chosen [19].
We expect considerable variation in the understanding
of ethical aspects and the methods employed. Therefore,
it might become necessary to adapt this list after a first
screening of the literature (but before in-depth analysis
of the publications identified).
Risk of bias assessment/quality
We will not assess the quality of HTA reports because
we focus on exploring methodological features of HTAs
on PHIs. We will include only HTAs that perform a sys-
tematic literature search and perform a critical appraisal
of included studies, which can be considered as minimal
requirements for HTA quality.
Data synthesis
We will tabulate data for each domain. The information
will be synthesized in a structured narrative way for the
respective domain and also across domains.
Statistics
We will describe dichotomous and nominal variables
using absolute numbers and percentages. We will pre-
pare means and standard deviations for metric variables.
For ordinal and skewed metric variables, we will calcu-
late median and ranges.
All analyses will be performed using SPSS 23 software.
Analysis of subgroups
We plan to perform two subgroup analyses. First, we
will consider HTAs on health promotion separately from
HTAs on primary prevention. Second, HTAs will be
analysed according to the different health care systems
(e.g. Beveridge model, Bismarck model, National Health
Insurance model), target audiences (e.g. physicians, pol-
icy decision makers) and evaluation level (e.g. hospital/
primary care, region, national) to identify justified meth-
odological differences (e.g. perspective of analysis, as-
sessment of applicability). We will code the subgroups
based on description of the intervention, country of ori-
gin, setting and perspective of the analysis.
Discussion
HTA is a tool to support policy decisions [20]. A
comprehensive and transparent assessment is in par-
ticular important in the field of public health because
the decision process often involves a large variety of
stakeholders.
The analysis will provide a comprehensive overview
of methods applied in HTAs on PHIs. We will get
insights into promising approaches for dealing with
the challenges when evaluating PHIs. Furthermore,
our work might identify important research gaps. This
analysis can stipulate further development and
harmonization of methods for HTAs on PHIs. An ad-
vancement of the methods can contribute to a higher
degree of acceptance of HTAs on PHIs by policy
makers and improved policy decision-making based
on the principles of evidence-based medicine.
We are aware that especially in the evaluation of a
PHI, social and ethical considerations should be ad-
dressed. Social and cultural norms influence how
people perceive a health issue and accept an interven-
tion and its implementation [15]. These might cause
differences in effectiveness between groups. To avoid
the exclusion of a majority of HTAs, we decided to
include also HTAs evaluating only effectiveness/safety
and economic aspects.
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Our work has some limitations. First, our focus on
health promotion and interventions for primary preven-
tion, as public health covers a broader field encompass-
ing environmental, behavioural and clinical interventions
for secondary and tertiary prevention. This decision was
made because we want a sample of HTAs that repre-
sents the specific characteristics of PHIs and allows un-
ambiguous differentiation from other medical fields.
While we have not found another satisfying way that
clearly distinguishes PHIs from other interventions, we
presume that our results are also applicable to other
PHIs. Second, the results of our analysis might be biased
toward European and North American countries be-
cause of our language restrictions. A third limitation is
that we will not arrive at a representative sample of
HTAs because of our strict inclusion criteria (full HTAs,
only literature-based HTAs). This decision was made be-
cause we deduced our inclusion criteria from a previous
work that analysed the methods in manuals for HTAs
on PHIs [8]. Thus, this work will provide only an extract
of “state of the art” methods. We acknowledge that these
methods are not always feasible because of lack of
resources to perform an in-depth analysis or lack of ap-
propriate literature.
In a future project, we will widen our scope and also
consider HTAs that only use accelerate review methods
(e.g. rapid reviews) or primary data analysis (e.g.
quasi-experimental designs, expert surveys).
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